Funding Announcement by VolitionRx Limited
VolitionRx Limited (NYSE AMERICAN: VNRX) has made headlines with its latest funding acquisition. The company, renowned for its contributions to epigenetics, secured $2 million through an agreement with Lind Global Asset Management XII LLC, an investor with notable backing from The Lind Partners.
Details of the Amended Agreement
The funding is structured around an amended purchase agreement that involves a senior secured convertible promissory note valued at $2.4 million. This indicates VolitionRx's confidence in its future prospects as it embarks on this unique financing route. The deal is not just a standard transaction; it includes a five-year warrant allowing the purchase of up to 7 million shares of the company's common stock at an attractive exercise price.
Investor Relationship
This partnership serves as a significant step forward for VolitionRx. The collaborative nature of this investment showcases the commitment of both parties to the ongoing research in the field of epigenetics and disease monitoring.
Reassessing Previous Agreements
The newly introduced agreement refines earlier arrangements, where the company previously issued a senior secured convertible note of $7.5 million. The evolution of these agreements amplifies VolitionRx's effort to enhance its operational capabilities and further its research agenda in early disease detection.
Future Payments and Obligations
Under the terms of the new deal, VolitionRx is expected to repay the promissory note through a series of monthly installments. Starting six months post-issuance, the company will make payments, which could be in cash or company stock. This flexibility aims to ease the financial pressure while potentially increasing share value.
Shareholder Benefits
The company’s approach promises to enhance shareholder value through potential stock appreciation associated with the new financing. The conversion terms set at $0.5714 per share offer an attractive entry point for investors looking to tap into the growth potential of VolitionRx.
VolitionRx's Commitment to Innovation
VolitionRx prides itself on advancing the science of epigenetics, focused on providing solutions for significant health challenges. The company is dedicated to the discovery and commercialization of blood tests aimed at the early detection of various diseases, including types of cancer.
About VolitionRx Limited
The mission of VolitionRx goes beyond profit; it is about making a life-saving difference. Through significant research and comprehensive studies in different geographical locations including Belgium and the U.S., VolitionRx aims to improve the quality of life for patients facing critical health crises.
Global Research Initiatives
Through its subsidiaries, VolitionRx is setting standards for the detection and monitoring of diseases. This global initiative reflects the company's ambition to not only contribute to the medical field but also to secure its standing as a leader in innovative health solutions.
Conclusion
This funding represents a pivotal moment for VolitionRx as it continues to innovate and expand its reach in the biotechnology sector. With financial support from committed investors, the company is poised for exciting developments that can shape the future of healthcare.
Frequently Asked Questions
What is the significance of the $2 million funding?
The funding will help VolitionRx enhance its research in epigenetics and advance innovative healthcare solutions.
Who is the investor involved in this agreement?
The investor is Lind Global Asset Management XII LLC, affiliated with The Lind Partners, known for institutional investing.
What is the repayment structure of the new promissory note?
The note will be repaid in eighteen consecutive monthly installments, starting six months after issuance.
How does this affect existing shareholders?
The investment could potentially enhance shareholder value by enabling further growth and development.
Where can VolitionRx’s research and facilities be found?
VolitionRx operates both research and innovation facilities in Belgium and the U.S., indicating a strong international presence.
